Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EBT Margin for 10 consecutive years, with 47.11% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 519.0% year-over-year to 47.11%, compared with a TTM value of 48.14% through Dec 2025, up 416.0%, and an annual FY2025 reading of 48.14%, up 416.0% over the prior year.
  • EBT Margin was 47.11% for Q4 2025 at Catalyst Pharmaceuticals, down from 47.87% in the prior quarter.
  • Across five years, EBT Margin topped out at 54.33% in Q4 2022 and bottomed at 37.03% in Q3 2023.
  • Average EBT Margin over 5 years is 40.23%, with a median of 44.94% recorded in 2022.
  • The sharpest move saw EBT Margin crashed -8246bps in 2023, then skyrocketed 8148bps in 2024.
  • Year by year, EBT Margin stood at 33.45% in 2021, then skyrocketed by 62bps to 54.33% in 2022, then fell by -22bps to 42.24% in 2023, then increased by 24bps to 52.31% in 2024, then dropped by -10bps to 47.11% in 2025.
  • Business Quant data shows EBT Margin for CPRX at 47.11% in Q4 2025, 47.87% in Q3 2025, and 47.28% in Q2 2025.